The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...